Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.58 |
| ▸ | DNM2 | P50570 | 9/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543215 | 0.98 | DNM2 (0.57) | TLR8DNM2NOS3NOS2ALDH1A1 | |
| SCHEMBL9313985 | 0.95 | TLR8 (0.65) | TLR8DNM2NOS3NOS2ALDH1A1 | |
| SCHEMBL12963699 | 0.87 | NOS3 (0.55) | TLR8DNM2NOS3NOS2ALDH1A1 | |
| SCHEMBL13989410 | 0.85 | TLR8 (0.61) | TLR8DNM2ALDH1A1MAPK1TP53 | |
| SCHEMBL11454656 | 0.81 | DNM2 (0.55) | TLR8DNM2NOS3NOS2ALDH1A1 | |
| SCHEMBL13309799 | 0.81 | TLR8 (0.61) | TLR8DNM2ALDH1A1MAPK1TP53 | |
| SCHEMBL13309832 | 0.81 | TLR8 (0.61) | TLR8DNM2ALDH1A1MAPK1TP53 | |
| SCHEMBL13309816 | 0.81 | TLR8 (0.61) | TLR8DNM2ALDH1A1MAPK1TP53 | |
| SCHEMBL1194281 | 0.81 | DNM2 (0.78) | TLR8DNM2ALDH1A1MAPK1TP53 | |
| SCHEMBL13309860 | 0.81 | TLR8 (0.61) | TLR8DNM2ALDH1A1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | TLR8 2752/4885DNM2 1992/4885NOS3 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.